<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Inventiva S.a — News on 6ix</title>
<link>https://6ix.com/company/inventiva-sa</link>
<description>Latest news and press releases for Inventiva S.a on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/inventiva-sa" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836175778dffbe2df13d7fc.webp</url>
<title>Inventiva S.a</title>
<link>https://6ix.com/company/inventiva-sa</link>
</image>
<item>
<title>Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor</title>
<link>https://6ix.com/company/inventiva-sa/news/inventiva-strengthens-leadership-team-ahead-of-expected-phase-3-data-readout-of-lanifibranor-1</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/inventiva-strengthens-leadership-team-ahead-of-expected-phase-3-data-readout-of-lanifibranor-1</guid>
<pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
<description>Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva’s organizational build-out as it advances toward</description>
</item>
<item>
<title>Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F</title>
<link>https://6ix.com/company/inventiva-sa/news/inventiva-announces-filing-of-its-2025-universal-registration-document-and-2025-annual-report-on-form-20-f</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/inventiva-announces-filing-of-its-2025-universal-registration-document-and-2025-annual-report-on-form-20-f</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), April 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage</description>
</item>
<item>
<title>Inventiva reports 2025 full year results and provides a business update</title>
<link>https://6ix.com/company/inventiva-sa/news/inventiva-reports-2025-full-year-results-and-provides-a-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/inventiva-reports-2025-full-year-results-and-provides-a-business-update</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Revenues of €4.5 million for the full year of 2025Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits1 as at December 31,</description>
</item>
<item>
<title>Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results</title>
<link>https://6ix.com/company/inventiva-sa/news/inventiva-schedules-the-publication-and-presentation-of-its-2025-full-year-financial-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/inventiva-schedules-the-publication-and-presentation-of-its-2025-full-year-financial-results-1</guid>
<pubDate>Mon, 23 Mar 2026 21:00:00 GMT</pubDate>
<description>Daix (France), New York (United States), March 23, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that it will release its 2025 full-year financial results on Monday, March 30, 2026, after market close in the United States. Inventiva’s management will hold a conference call in Eng</description>
</item>
<item>
<title>Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results </title>
<link>https://6ix.com/company/inventiva-sa/news/inventiva-schedules-the-publication-and-presentation-of-its-2025-full-year-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/inventiva-schedules-the-publication-and-presentation-of-its-2025-full-year-financial-results</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Daix (France), New York (United States), March 23, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage</description>
</item>
<item>
<title>Inventiva to Participate in Four Upcoming March Investor Conferences</title>
<link>https://6ix.com/company/inventiva-sa/news/inventiva-to-participate-in-four-upcoming-march-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/inventiva-to-participate-in-four-upcoming-march-investor-conferences</guid>
<pubDate>Thu, 26 Feb 2026 21:14:00 GMT</pubDate>
<description>Daix (France), New York (United States), February 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference</description>
</item>
<item>
<title>Inventiva reports preliminary 2025¹ fiscal year financial results</title>
<link>https://6ix.com/company/inventiva-sa/news/inventiva-reports-preliminary-2025-fiscal-073000114</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/inventiva-reports-preliminary-2025-fiscal-073000114</guid>
<pubDate>Tue, 17 Feb 2026 07:30:00 GMT</pubDate>
<description>Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5 million in 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million3)Cash runway expected until the middle of the first quarter of 20274 Daix (France), New York City (New York, United States), February 17, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceu</description>
</item>
<item>
<title>Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/inventiva-sa/news/inventiva-present-guggenheim-emerging-outlook-biotech-summit-2026-2026-02-04-0</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/inventiva-present-guggenheim-emerging-outlook-biotech-summit-2026-2026-02-04-0</guid>
<pubDate>Wed, 04 Feb 2026 05:00:00 GMT</pubDate>
<description>Daix (France), New York (United States), February 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage</description>
</item>
<item>
<title>Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux</title>
<link>https://6ix.com/company/inventiva-sa/news/half-year-review-inventivas-liquidity-contract-kepler-cheuvreux-2026-01-26</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/half-year-review-inventivas-liquidity-contract-kepler-cheuvreux-2026-01-26</guid>
<pubDate>Mon, 26 Jan 2026 05:00:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a</description>
</item>
<item>
<title>Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/inventiva-sa/news/inventiva-present-44th-annual-jp-morgan-healthcare-conference-2025-12-17-0</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/inventiva-present-44th-annual-jp-morgan-healthcare-conference-2025-12-17-0</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), December 17, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a</description>
</item>
<item>
<title>Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025</title>
<link>https://6ix.com/company/inventiva-sa/news/results-votes-combined-shareholders-general-meeting-november-27-2025-2025-11-28-0</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/results-votes-combined-shareholders-general-meeting-november-27-2025-2025-11-28-0</guid>
<pubDate>Fri, 28 Nov 2025 05:00:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage</description>
</item>
<item>
<title>Information relating to the stabilization activities carried out in the context of its recent offering</title>
<link>https://6ix.com/company/inventiva-sa/news/information-relating-stabilization-activities-carried-out-context-its-recent-offering</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/information-relating-stabilization-activities-carried-out-context-its-recent-offering</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), November 24, 2025 – Publication of information relating to the stabilization activities carried out in</description>
</item>
<item>
<title>Inventiva reports 2025 Third Quarter Financial Information¹</title>
<link>https://6ix.com/company/inventiva-sa/news/inventiva-reports-2025-third-quarter-financial-information1-2025-11-21-0</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/inventiva-reports-2025-third-quarter-financial-information1-2025-11-21-0</guid>
<pubDate>Fri, 21 Nov 2025 05:00:00 GMT</pubDate>
<description>Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits2 as of September 30, 2025.Revenues of €4.5 million for the first nine</description>
</item>
<item>
<title>Inventiva announces full exercise of Underwriters’ Option, bringing proceeds of Offering to approximately $172.5M</title>
<link>https://6ix.com/company/inventiva-sa/news/inventiva-announces-full-exercise-underwriters-option-bringing-proceeds-offering-0</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/inventiva-announces-full-exercise-underwriters-option-bringing-proceeds-offering-0</guid>
<pubDate>Mon, 17 Nov 2025 05:00:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a</description>
</item>
<item>
<title>Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares</title>
<link>https://6ix.com/company/inventiva-sa/news/inventiva-announces-pricing-upsized-public-offering-approximately-150m-american-0</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/inventiva-announces-pricing-upsized-public-offering-approximately-150m-american-0</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a</description>
</item>
<item>
<title>Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris</title>
<link>https://6ix.com/company/inventiva-sa/news/inventiva-announces-temporary-trading-halt-its-ordinary-shares-euronext-paris-2025-0</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/inventiva-announces-temporary-trading-halt-its-ordinary-shares-euronext-paris-2025-0</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a</description>
</item>
<item>
<title>Inventiva announces trading resumption of its ordinary shares on Euronext Paris</title>
<link>https://6ix.com/company/inventiva-sa/news/inventiva-announces-trading-resumption-its-ordinary-shares-euronext-paris-2025-11-0</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/inventiva-announces-trading-resumption-its-ordinary-shares-euronext-paris-2025-11-0</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a</description>
</item>
<item>
<title>Inventiva announces launch of public offering</title>
<link>https://6ix.com/company/inventiva-sa/news/inventiva-announces-launch-public-offering-2025-11-12-0</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/inventiva-announces-launch-public-offering-2025-11-12-0</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), November 12, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a</description>
</item>
<item>
<title>Statement of total voting rights and shares forming the company’s share capital as October 20, 2025</title>
<link>https://6ix.com/company/inventiva-sa/news/statement-total-voting-rights-and-shares-forming-companys-share-capital-october-20-0</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/statement-total-voting-rights-and-shares-forming-companys-share-capital-october-20-0</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Article R. 22-10-23 of the French Commercial Code Market : Euronext ParisISIN code / Mnemo : FR0013233012 / IVAWeb site : www.inventivapharma.com Date Number</description>
</item>
<item>
<title>Combined General Meeting of November 27, 2025 - Availability of the preparatory documents</title>
<link>https://6ix.com/company/inventiva-sa/news/combined-general-meeting-november-27-2025-availability-preparatory-documents-2025-0</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa/news/combined-general-meeting-november-27-2025-availability-preparatory-documents-2025-0</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), November 6, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company”), a</description>
</item>
</channel>
</rss>